Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) has been awarded a $100,000 voucher to support the manufacture of clinical diagnostic tests in Western Australia. The funding targets future local production of Proteomics International’s PromarkerD blood test, the world’s first predictive diagnostic test for diabetic kidney disease.
The funding, Awarded through the MTPConnect WA Life Sciences Innovation Hub, will be used to establish additional ISO 13485 quality control processes for manufacture of the immunoassay version of the PromarkerD test.
